Agreement - February 26, 2024
Kancera resolves on a right issue and enters license agreement
The board of directors of Kancera has resolved on a new share issue with preferential rights for the company’s existing shareholders of approximately SEK 121.9 million. The objective of the Rights Issue is to secure resources to advance the company’s development program, consisting of the candidate drugs KAND567 and KAND145, to start of new clinical […]
Agreement - February 14, 2024
DelSiTech enters agreement with Tolmar
The two companies have announced the signing of a global license and development agreement, further strengthening their collaboration, following investment from Tolmar in January 2024. Under the terms of the Agreement, Tolmar will obtain a global license to utilize DelSiTech’s proprietary, silica-based, drug delivery technology platform for the development and commercialization of two undisclosed long-acting […]
Agreement - February 13, 2024
Sobi and Handok establish joint venture for rare disease business
The joint venture will commercialize and distribute selected Sobi medicines in South Korea. The joint venture, due for incorporation in the first half of this year, is expected to enhance the Sobi and Handok collaboration, they state. Strengthening their position in the rare disease business, Handok and Sobi aim to develop, commercialize and distribute Sobi’s […]
Agreement - February 5, 2024
Biovian and 3P Biopharmaceuticals join forces
The two biologics Contract Development and Manufacturing Organizations (CDMOs), have announced their combination. Backed by their common shareholder, Keensight Capital, the combination of Biovian and 3P extends the group’s value proposition to address complex customer needs across the entire development cycle, the companies state. Keensight Capital will continue to help the Group strengthen its position […]
Agreement - February 4, 2024
Orion enters licensing agreement with Newel Health
Orion Corporation and Newel Health have entered into a license agreement regarding ODD-403, a digital therapeutic (DTx) developed by Orion for patients suffering from chronic pain and particularly from fear of movement and re-injury. Under the terms of the agreement, Newel will have the exclusive global rights to develop, manufacture and commercialize ODD-403. Orion is […]
Agreement - January 24, 2024
Novo Nordisk enters agreement with EraCal Therapeutics
Novo Nordisk has entered into a collaboration and license agreement with the Swiss company EraCal Therapeutics. The two companies will develop and commercialize EraCal’s oral, small molecule program. The asset is believed to target a novel mechanism of action controlling appetite and body weight to treat obesity. Milestones of up to EUR 235 million Novo […]
